These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37931493)

  • 1. Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Takeshita N; Enokida T; Okano S; Fujisawa T; Wada A; Sato M; Tanaka H; Tanaka N; Onaga R; Hoshi Y; Sakashita S; Ishii G; Tahara M
    Oral Oncol; 2023 Dec; 147():106615. PubMed ID: 37931493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
    Tahara M; Kiyota N; Yokota T; Hasegawa Y; Muro K; Takahashi S; Onoe T; Homma A; Taguchi J; Suzuki M; Minato K; Yane K; Ueda S; Hara H; Saijo K; Yamanaka T
    Ann Oncol; 2018 Apr; 29(4):1004-1009. PubMed ID: 29408977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma.
    Chen TH; Pan YY; Lee TL; Wang LW; Tai SK; Chu PY; Lo WL; Wu CH; Yang MH; Chang PM
    BMC Cancer; 2022 Dec; 22(1):1336. PubMed ID: 36539738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
    Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
    Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.
    Guo Y; Luo Y; Zhang Q; Huang X; Li Z; Shen L; Feng J; Sun Y; Yang K; Ge M; Zhu X; Wang L; Liu Y; He X; Bai C; Xue K; Zeng Y; Chang X; Chen W; Lin T
    Eur J Cancer; 2021 Oct; 156():35-45. PubMed ID: 34418665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboplatin and paclitaxel after anti-PD-1 or anti-PD-L1 antibody therapy in recurrent and/or metastatic squamous cell carcinoma of head and neck.
    Humphries A; Zhou CJ; Welsh M; Lem M; Kang H; Algazi AP
    Head Neck; 2024 Feb; 46(2):321-327. PubMed ID: 37997549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
    Haddad RI; Harrington K; Tahara M; Ferris RL; Gillison M; Fayette J; Daste A; Koralewski P; Zurawski B; Taberna M; Saba NF; Mak M; Kawecki A; Girotto G; Alvarez Avitia MA; Even C; Toledo JGR; Guminski A; Müller-Richter U; Kiyota N; Roberts M; Khan TA; Miller-Moslin K; Wei L; Argiris A
    J Clin Oncol; 2023 Apr; 41(12):2166-2180. PubMed ID: 36473143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Wada A; Enokida T; Okano S; Sato M; Tanaka H; Ueda Y; Fujisawa T; Takeshita N; Tanaka N; Tahara M
    Eur J Cancer; 2023 May; 184():30-38. PubMed ID: 36898232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer.
    Cabezas-Camarero S; Cabrera-Martín MN; Merino-Menéndez S; Paz-Cabezas M; García-Barberán V; Sáiz-Pardo Sanz M; Iglesias-Moreno M; Alonso-Ovies A; Pérez-Segura P
    Oncologist; 2021 Jun; 26(6):e1018-e1035. PubMed ID: 33751752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
    Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
    [No Abstract]   [Full Text] [Related]  

  • 11. Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
    Chevalier T; Daste A; Saada-Bouzid E; Loundou A; Peyraud F; Lambert T; Le Tourneau C; Peyrade F; Dupuis C; Alfonsi M; Fayette J; Reure J; Huguet F; Fakhry N; Toullec C; Salas S
    Cancer Med; 2021 Jun; 10(12):3952-3963. PubMed ID: 34080776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial.
    Zheng Y; Dou H; Li Q; Sun Y; Wang Y; Zhang W
    Cancer Control; 2021; 28():1073274821997444. PubMed ID: 34029149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
    Ferris RL; Licitra L; Fayette J; Even C; Blumenschein G; Harrington KJ; Guigay J; Vokes EE; Saba NF; Haddad R; Ramkumar S; Russell J; Brossart P; Tahara M; Colevas AD; Concha-Benavente F; Lynch M; Li L; Gillison ML
    Clin Cancer Res; 2019 Sep; 25(17):5221-5230. PubMed ID: 31239321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Bossi P; Miceli R; Locati LD; Ferrari D; Vecchio S; Moretti G; Denaro N; Caponigro F; Airoldi M; Moro C; Vaccher E; Sponghini A; Caldara A; Rinaldi G; Ferrau F; Nolè F; Lo Vullo S; Tettamanzi F; Hollander L; Licitra L
    Ann Oncol; 2017 Nov; 28(11):2820-2826. PubMed ID: 28950305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of weekly paclitaxel-cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors.
    Bernad IP; Trufero JM; Urquizu LC; Pazo Cid RA; de Miguel AC; Agustin MJ; Lanzuela M; Antón A
    Clin Transl Oncol; 2017 Jun; 19(6):769-776. PubMed ID: 28120324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.
    Weiss J; Gilbert J; Deal AM; Weissler M; Hilliard C; Chera B; Murphy B; Hackman T; Liao JJ; Grilley Olson J; Hayes DN
    Oral Oncol; 2018 Sep; 84():46-51. PubMed ID: 30115475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial.
    Adkins D; Ley J; Atiq O; Powell S; Spanos WC; Gitau M; Rigden C; Palka K; Liu J; Oppelt P
    Oral Oncol; 2021 Apr; 115():105173. PubMed ID: 33548860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the benefit of salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck.
    Reverdy T; Varnier R; de Talhouët S; Duplomb S; Bruyas A
    Oral Oncol; 2023 Oct; 145():106533. PubMed ID: 37562096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.
    Koyama T; Kiyota N; Boku S; Imamura Y; Shibata N; Satake H; Tanaka K; Hayashi H; Onoe T; Asada Y; Yamazaki T; Nose T; Ohata S; Nagatani Y; Kimbara S; Funakoshi Y; Teshima M; Shinomiya H; Minami H
    ESMO Open; 2024 Jun; 9(6):103476. PubMed ID: 38833968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.